NASDAQ$OMER
Omeros Corp · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Omeros reported a net loss for Q1 2024 and highlighted progress in clinical programs and financial achievements.
Omeros Corporation reported a net loss of $37.2 million for the first quarter of 2024. The company received $115.5 million in cash from an amended royalty agreement with DRI Healthcare Acquisitions LP. They are advancing clinical programs for OMS906 and OMS527, and working towards resubmission of the BLA for narsoplimab.
- Net loss for the first quarter of 2024 was $37.2 million, or $0.63 per share.
- Received $115.5 million from DRI Healthcare after amending the OMIDRIA royalty purchase agreement.
- Cash and short-term investments totaled $230.3 million as of March 31, 2024.
- Continued engagement with the FDA regarding the analysis plan for resubmission of the BLA for narsoplimab in TA-TMA.
Headline financials
Revenue & EPS history
Omeros · Revenue · Quarterly
$388K
Revenue by segment
Omeros · $31.9M total across 1 segment · Q4 2021
- OMIDRIA royalties$31.9M—100.0%
Forward guidance
Omeros is focused on advancing its clinical programs, particularly OMS906 in PNH and C3G, and resubmitting the BLA for narsoplimab in TA-TMA. They are also progressing OMS1029 and OMS527.
Tailwinds
- Cash runway extended into 2026 through the sale of a portion of OMIDRIA royalties.
- Phase 2 program for OMS906 in PNH is fully enrolled and Phase 3 program is on track for late 2024 initiation.
- Phase 2 clinical trial in C3G has begun enrollment with a Phase 3 program targeted for early 2025.
- OMS1029 is ready to begin a Phase 2 program later in the year.
- PDE7 inhibitor program OMS527 is advancing on schedule, fully funded by NIDA.
Headwinds
- Uncertainty regarding the timing of the resubmission of the BLA for narsoplimab and FDA's decision.
- Dependence on ongoing discussions with the FDA regarding the analysis plan for narsoplimab.
- Challenges associated with manufacture or supply of investigational or clinical products.
- Potential changes in reimbursement and payment policies by government and commercial payers.
- Risks related to intellectual property claims and competitive developments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
+2.3%
Avg return
Earnings day
+4.9%
Avg return
5 days after
+9.4%
Avg return
30 days after
42%
27 / 64 earnings
Positive
+64.2%
Q4 2019
Best reaction
-21.2%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -20.8% | — | |
| Q4 2025 | +7.5% | +3.1% | +42.6% | |
| Q3 2025 | +26.3% | +30.9% | +61.6% | |
| Q1 2025 | -18.7% | -21.3% | -13.9% | |
| Q4 2024 | -3.8% | -14.1% | -14.6% | |
| Q3 2024 | +63.1% | +39.0% | +79.1% | |
| Q2 2024 | -10.5% | -2.1% | -16.7% | |
| Q1 2024 | -21.2% | -21.4% | -3.3% | |
| Q4 2023 | -11.6% | -0.6% | -1.4% | |
| Q3 2023 | -3.8% | +14.6% | +97.7% | |
| Q2 2023 | -1.2% | -6.1% | -20.7% | |
| Q1 2023 | +21.2% | +14.2% | +51.4% | |
| Q4 2022 | +15.6% | +8.6% | +72.1% | |
| Q3 2022 | -16.9% | -10.9% | -35.6% | |
| Q2 2022 | +10.5% | +5.6% | -19.4% | |
| Q1 2022 | -5.4% | +15.9% | -22.5% | |
| Q4 2021 | -5.1% | -11.2% | -16.5% | |
| Q3 2021 | +7.6% | +10.1% | +6.3% | |
| Q2 2021 | +1.5% | +4.4% | +5.3% | |
| Q1 2021 | +3.8% | +2.5% | -9.6% | |
| Q4 2020 | +1.2% | -7.3% | -10.7% | |
| Q3 2020 | +6.1% | +11.3% | +37.0% | |
| Q2 2020 | +12.5% | -4.0% | -22.2% | |
| Q1 2020 | -6.2% | -12.0% | -2.2% | |
| Q4 2019 | +64.2% | +51.8% | +8.7% | |
| Q3 2019 | +2.2% | -3.9% | -3.9% | |
| Q2 2019 | +14.7% | +20.6% | +14.4% | |
| Q1 2019 | +5.1% | +0.9% | -8.3% | |
| Q4 2018 | +12.5% | +9.2% | +20.5% | |
| Q3 2018 | -20.3% | -22.2% | -14.2% | |
| Q2 2018 | -18.0% | -4.7% | +16.9% | |
| Q1 2018 | +18.0% | +45.0% | +8.7% | |
| Q4 2017 | -0.9% | -0.1% | +10.6% | |
| Q3 2017 | +27.5% | +33.1% | +37.5% | |
| Q2 2017 | +12.4% | +5.9% | -6.8% | |
| Q1 2017 | -7.7% | -6.4% | -4.7% | |
| Q4 2016 | -7.9% | -2.9% | +34.7% | |
| Q3 2016 | +28.7% | +45.8% | +9.4% | |
| Q2 2016 | +3.0% | -7.9% | -8.9% | |
| Q1 2016 | -15.0% | — | — | |
| Q4 2015 | +24.7% | — | — | |
| Q3 2015 | -1.3% | — | — | |
| Q2 2015 | -3.1% | — | — | |
| Q1 2015 | +4.8% | — | — | |
| Q4 2014 | -6.2% | — | — | |
| Q3 2014 | +9.7% | — | — | |
| Q2 2014 | -5.7% | — | — | |
| Q1 2014 | -6.9% | — | — | |
| Q4 2013 | -11.7% | — | — | |
| Q3 2013 | -5.6% | — | — | |
| Q2 2013 | -7.2% | — | — | |
| Q1 2013 | +17.5% | — | — | |
| Q4 2012 | -3.7% | — | — | |
| Q3 2012 | -17.1% | — | — | |
| Q2 2012 | -2.2% | — | — | |
| Q1 2012 | -0.6% | — | — | |
| Q4 2011 | -3.5% | — | — | |
| Q3 2011 | -2.0% | — | — | |
| Q2 2011 | +3.0% | — | — | |
| Q1 2011 | -0.8% | — | — | |
| Q4 2010 | -3.8% | — | — | |
| Q3 2010 | -3.2% | — | — | |
| Q2 2010 | -12.3% | — | — | |
| Q1 2010 | -3.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro